ChiCTR2100049315
正在进行
/
/
/
2021-07-30
/
/
Borderline Personality Disorder; Pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.)
DBT in Hong Kong Mental Health Community Setting
The Effectiveness of Dialectical Behavior Therapy in a Mental Health Community Setting in Hong Kong
Dialectical Behavior Therapy (DBT) is an evidence-based treatment for individuals with symptoms of different psychiatric diagnoses (e.g., Cristea et al., 2017), particular those at risks for suicide or parasuicidal behavior (e.g., DeCou et al., 2019; Stanley et al., 2007) and those reporting emotion dysregulation (e.g., Kells et al., 2020). A transdiagnostic treatment that meets the needs of clinical populations at various risk levels can potentially mitigate the associated high cost to the health system as a whole. Considering the various components of DBT, establishment of a standard DBT program can be a multi-phasic project. Stand-alone DBT skills training groups have been found effective in reducing symptoms of mental health disorders (Valentine et al., 2014) and strengthening emotion regulation (Kells et al., 2020). Therefore, this study serves as a pilot and focuses on the effectiveness of skills training groups. Preliminary data collected will not only inform the projects subsequent phase(s) of expansion into a standard DBT program but also shed light on the implementation of DBT in an outpatient community setting in Hong Kong.
单臂
Ⅲ期
N/A
N/A
Lump sum grant
/
50
/
2021-07-14
2026-03-31
/
- Aged 18 years or up; - Speak, read, and write Chinese; - Meet diagnostic criteria of Borderline Personality Disorder; OR show traits of pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.); - Present treatment needs related to Stage 1 treatment targets as defined in DBT, such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Show elevation on screening measures such as the Borderline Symptom List 23 (BSL-23).；
请登录查看- Present with active psychosis without insight; - Demonstrate sub-average intelligence; - Decline to commit on Stage 1 treatment targets; that is, targets related to areas such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Concurrently receive other psychological services.；
请登录查看新生活精神康復協會
/
医药经济报2025-12-12
医学新视点2025-12-12
上海拓界生物医药2025-12-12
绽妍JUYOU2025-12-12
隆门资本2025-12-12
信邦制药2025-12-12
君实医学2025-12-12
触界生物2025-12-12
标新生物GLUETACS2025-12-12
兽药资讯2025-12-12
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
